FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a group of inventions involving using 1-{4-[1-(4-cyclohexyl-3-trifluoromethylbenzyloxyimino)ethyl]-2-benzylethyl}azetidine-3-carboxylic acid, its N-oxide, or a mixture of isomers, its salts, solvates or hydrates for preparing a drug for preventing, inhibiting or treating an inflammatory condition specified in polymyosite and dermatopolymyosite (versions), a related method of treating, and a pharmaceutical composition for the same application containing the above compound.
EFFECT: what has been shown is an almost complete block of cytokine-induced amyotrophia.
4 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOSUPPRESSIVE COMPOUNDS AND COMPOSITIONS | 2004 |
|
RU2405768C2 |
| DOSAGE REGIMEN OF RECEPTOR S1P AGONIST | 2009 |
|
RU2561681C2 |
| LIQUID FORMULATIONS | 2006 |
|
RU2470631C2 |
| COMPOUNDS AND COMPOSITIONS AS CANNABINOID RECEPTOR 1 INHIBITORS | 2005 |
|
RU2431635C2 |
| COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
| COMPOUNDS AND COMPOSITIONS AS MODULATORS OF ACTIVATED RECEPTORS OF PEROXISOME PROLIFERATOR | 2005 |
|
RU2413723C2 |
| COMPOUNDS AND COMPOSITIONS AS PEROXISOME PROLIFERATOR RECEPTOR MODULATORS | 2005 |
|
RU2412175C2 |
| LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
| IDENTIFICATION OF PATIENTS' REACTION TO ADMINISTRATION OF S1P RECEPTOR MODULATOR | 2013 |
|
RU2785736C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2005 |
|
RU2406725C2 |
